These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 34134873)
1. Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities. Marsh JC; Amaro H; Kong Y; Khachikian T; Guerrero E J Subst Abuse Treat; 2021 Aug; 127():108399. PubMed ID: 34134873 [TBL] [Abstract][Full Text] [Related]
2. Gender disparities in opioid treatment progress in methadone versus counseling. Guerrero E; Amaro H; Kong Y; Khachikian T; Marsh JC Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):52. PubMed ID: 34162420 [TBL] [Abstract][Full Text] [Related]
3. Disparities in opioid treatment access and retention among women based on pregnancy status from 2006 to 2017. Khachikian T; Amaro H; Guerrero E; Kong Y; Marsh JC Drug Alcohol Depend Rep; 2022 Mar; 2():. PubMed ID: 35369381 [TBL] [Abstract][Full Text] [Related]
4. Gender-specific predictors of methadone treatment outcomes among African Americans at an urban clinic. Lister JJ; Brown S; Greenwald MK; Ledgerwood DM Subst Abus; 2019; 40(2):185-193. PubMed ID: 30888262 [No Abstract] [Full Text] [Related]
5. Identifying gender differences in risk profiles and in opioid treatment outcomes in Los Angeles County. Amaro H; Kong Y; Marsh JC; Khachikian T; Guerrero EG Eval Program Plann; 2023 Apr; 97():102240. PubMed ID: 36702006 [TBL] [Abstract][Full Text] [Related]
6. Barriers to retention in medications for opioid use disorder treatment in real-world practice. Villamil VI; Underwood N; Cremer LJ; Rooks-Peck CR; Jiang X; Guy GP J Subst Use Addict Treat; 2024 May; 160():209310. PubMed ID: 38331319 [TBL] [Abstract][Full Text] [Related]
7. Geographic variation in availability of opioid treatment programs across U.S. communities. Jehan S; Zahnd WE; Wooten NR; Seay KD J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315 [TBL] [Abstract][Full Text] [Related]
8. Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study. Knight D; Nkya IH; West NS; Yang C; Kidorf M; Latkin C; Saleem HT Addict Sci Clin Pract; 2023 Mar; 18(1):19. PubMed ID: 36973794 [TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Hansen H; Siegel C; Wanderling J; DiRocco D Drug Alcohol Depend; 2016 Jul; 164():14-21. PubMed ID: 27179822 [TBL] [Abstract][Full Text] [Related]
10. Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services. Moran L; Keenan E; Elmusharaf K BMC Health Serv Res; 2018 Nov; 18(1):911. PubMed ID: 30497467 [TBL] [Abstract][Full Text] [Related]
11. The case for a medication first approach to the treatment of opioid use disorder. Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515 [No Abstract] [Full Text] [Related]
12. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967 [TBL] [Abstract][Full Text] [Related]
13. Experiences of Aging with Opioid Use Disorder and Comorbidity in Opioid Treatment Programs: A Qualitative Analysis. Han BH; Orozco MA; Miyoshi M; Doland H; Moore AA; Jones KF J Gen Intern Med; 2024 Jul; 39(9):1673-1680. PubMed ID: 38436883 [TBL] [Abstract][Full Text] [Related]
14. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146 [TBL] [Abstract][Full Text] [Related]
15. Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016. Askari MS; Martins SS; Mauro PM J Subst Abuse Treat; 2020 Jul; 114():108028. PubMed ID: 32527510 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of State Targeted/Opioid Response Grants and the Medication First Approach: Evidence of Racial Inequities in Improved Treatment Access and Retention. Winograd R; Budesa Z; Banks D; Carpenter R; Wood CA; Duello A; Thater P; Smith C Subst Abus; 2023 Jul; 44(3):184-195. PubMed ID: 37702074 [TBL] [Abstract][Full Text] [Related]
17. Trends and Disparities in Perinatal Opioid Use Disorder Treatment in Medicaid, 2007-2012. Landis RK; Stein BD; Dick AW; Griffin BA; Saloner BK; Terplan M; Faherty LJ Med Care Res Rev; 2024 Apr; 81(2):145-155. PubMed ID: 38160405 [TBL] [Abstract][Full Text] [Related]
18. Workforce Diversity and disparities in wait time and retention among opioid treatment programs. Guerrero EG; Kong Y; Frimpong JA; Khachikian T; Wang S; D'Aunno T; Howard DL Subst Abuse Treat Prev Policy; 2022 Nov; 17(1):74. PubMed ID: 36384761 [TBL] [Abstract][Full Text] [Related]
19. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834 [TBL] [Abstract][Full Text] [Related]
20. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]